Tagged with Switzerland

Switzerland www.celonic.com CEO of Swiss biologics CDMO Celonic, Konstantin Matentzoglu, explains how the company attracts talented and experienced staff and what makes it the partner of choice in Switzerland and beyond. Celonic is in many ways more than a CDMO for biologics. What is the strategic focus of this company? “Our…

Switzerland As the largest privately owned pharmaceutical company in Switzerland, IBSA remains committed to continuing to invest and manufacture in Switzerland. Head of Swiss Business Operations Maleša Ulrico Sidjanski, MSc ETH, discusses the company’s current priorities, values, and upcoming investments.   What other mid-sized multinational pharmaceutical companies present in over 80…

Switzerland Jesús Martin-Garcia, Chairman and CEO of GeNeuro, discusses their positive partnership with Servier to develop an antibody against a possible cause of MS, as well as the reasons for choosing Geneva when working with multiple sclerosis. Following 15 years of research performed by French-based Institut Mérieux and INSERM, GeNeuro was…

Switzerland Managing volatility – the CEO of Acino, a Swiss pharmaceutical player, elaborates on the company’s unique strategy based on its significant expertise in volatile and uncertain key markets within their regions. Most of your career has been spent with mid-cap and big pharmaceutical companies. Three years ago, you decided to…

Switzerland The Services Delivery Director for Life Sciences of NNIT Switzerland talks big data and highlights how this trend needs to be approached in order to create value for companies in the life science industry. You first joined NNIT in 2010; you then moved to the FMCG sector for a few…

Switzerland Daniel Schmutz, CEO of Switzerland’s leading insurance company, Helsana, sketches out the Swiss health insurance landscape, how his company maintains its market leader position, and working with both national and international partners to create better products for its customers and a more efficient insurance system. With 1.9 million policy takers…

Switzerland LEO Pharma’s Country Lead for Switzerland, Patrick Brunner, discusses the skincare specialist’s most important products, the Swiss affiliate’s significance to the global group, and the exciting new partnership with AstraZeneca. LEO Pharma Switzerland was established back in 1991 meaning that, last year, you celebrated 25 years of in-country operations. Could…

Switzerland The President of FASMED—the Swiss medical technology industry and trade association—elaborates on the plans to join forces with Medical Cluster, the other national medical technology organization, and highlights the current challenges facing the industry in Switzerland. Mr Gasche, you have a very interesting background, in the sense that you have…

Switzerland Ensuring a fair allocation of rights and returns from collaboratively developed technologies is a continual challenge for university Tech Transfer Offices – swiTT president Stefan Kohler discusses the current challenges and shares his perspective on the role of university developed IP in the Swiss life science ecosystem. What are some…

Switzerland Beat Berger (BB) and Dr Uwe Schmelzer (US) of Swiss API distributor DCS Pharma discuss growth segments in the global generics market, international hotspots, and the benefits of being based in Switzerland.   As an API distributor, what segments of the global generics market do you see the most growth…

Switzerland Not all impactful innovation involves the development of new chemical or biological entities, and the value of such innovation must be recognized in pricing processes argues Gebro Pharma Switzerland CEO Marcel Plattner. We understand you serve as the head of the executive committee for market access and pricing within the…

Switzerland Ulf Claesson provides a fascinating and passionate account of how his firm is aiming to remove ‘guesswork’ and estimations for medical practices whilst highlighting interesting developments in the global clinical research industry. To begin with, we understand that you are a bit of a spin-out & start-up artist, and have…